Total Payments
$253,912
2024 Payments
$1,563
Companies
13
Transactions
139
Medicare Patients
270
Medicare Billing
$48,386
Payment Breakdown by Category
Consulting$153,546 (60.5%)
Research$63,335 (24.9%)
Travel$21,961 (8.6%)
Other$11,863 (4.7%)
Food & Beverage$2,613 (1.0%)
Education$594.78 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $153,546 | 41 | 60.5% |
| Unspecified | $63,335 | 19 | 24.9% |
| Travel and Lodging | $21,961 | 29 | 8.6% |
| Honoraria | $9,050 | 2 | 3.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,813 | 2 | 1.1% |
| Food and Beverage | $2,613 | 45 | 1.0% |
| Education | $594.78 | 1 | 0.2% |
Payments by Type
General
$190,577
120 transactions
Research
$63,335
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UCB SA | $94,223 | 10 | $0 (2023) |
| UCB, Inc. | $71,612 | 41 | $0 (2024) |
| LivaNova USA, Inc. | $55,259 | 24 | $0 (2023) |
| Cyberonics, Inc. | $8,750 | 2 | $0 (2017) |
| Greenwich Biosciences, Inc. | $7,364 | 11 | $0 (2021) |
| Lundbeck LLC | $5,829 | 8 | $0 (2017) |
| SK Life Science, Inc. | $5,825 | 13 | $0 (2020) |
| UCB Biosciences Inc. | $2,179 | 10 | $0 (2019) |
| UCB GmBH | $1,347 | 8 | $0 (2017) |
| Medtronic USA, Inc. | $1,082 | 8 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,563 | 3 | UCB, Inc. ($1,280) |
| 2023 | $17,808 | 5 | UCB, Inc. ($6,311) |
| 2022 | $17,443 | 7 | UCB, Inc. ($12,580) |
| 2021 | $62,209 | 17 | UCB SA ($35,256) |
| 2020 | $46,101 | 24 | UCB SA ($15,123) |
| 2019 | $62,176 | 40 | UCB SA ($32,832) |
| 2018 | $14,187 | 20 | LivaNova USA, Inc. ($11,988) |
| 2017 | $32,425 | 23 | LivaNova USA, Inc. ($16,498) |
All Payment Transactions
139 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | NEUROPACE, INC. | RNS Neurostimulator Kit (Device) | Food and Beverage | In-kind items and services | $182.88 | General |
| Category: Epilepsy | ||||||
| 12/07/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $99.65 | General |
| Category: NEUROLOGY | ||||||
| 05/15/2024 | UCB, Inc. | Nayzilam (Drug) | Consulting Fee | Cash or cash equivalent | $1,280.00 | General |
| Category: Neurology | ||||||
| 05/30/2023 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Travel and Lodging | Cash or cash equivalent | $3,983.75 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/30/2023 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Travel and Lodging | Cash or cash equivalent | $576.32 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/10/2023 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,311.25 | General |
| 03/17/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $6,311.25 | General |
| 01/06/2023 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $625.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/05/2022 | LivaNova USA, Inc. | VNS Therapy SenTiva Model 1000 Generator (Device) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/02/2022 | NEUROPACE, INC. | RNS Neurostimulator Kit (Device) | Food and Beverage | In-kind items and services | $140.68 | General |
| Category: Epilepsy | ||||||
| 09/22/2022 | UCB, Inc. | — | — | In-kind items and services | $2,300.00 | Research |
| Study: Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: Results of a phase 3, open-label extension trial | ||||||
| 03/10/2022 | UCB, Inc. | — | — | Cash or cash equivalent | $3,680.00 | Research |
| Study: EXCHANGE OF CLINICAL PRACTICE AND REAL-LIFE TREATMENT WITH BRIVARACETAM (EXPERIENCE) | ||||||
| 02/14/2022 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 01/19/2022 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $4,700.00 | General |
| 01/04/2022 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| 12/02/2021 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| 11/16/2021 | UCB, Inc. | Briviact (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Neurology | ||||||
| 10/11/2021 | UCB, Inc. | — | — | In-kind items and services | $420.00 | Research |
| Study: 12-month effectiveness and tolerability of brivaracetam in the real-world: interim analysis of the international, non-interventional EXPERIENCE study | ||||||
| 08/24/2021 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| 08/02/2021 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,062.50 | General |
| 06/28/2021 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,025.00 | General |
| 06/25/2021 | Greenwich Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $833.00 | General |
| 06/14/2021 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 06/09/2021 | UCB, Inc. | Briviact (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Neurology | ||||||
| 05/28/2021 | UCB SA | Briviact (Drug) | Consulting Fee | Cash or cash equivalent | $17,628.00 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRIVARACETAM ADMINISTERED INTRAVENOUSLY AS TREATMENT FOR INCREASED SEIZURE ACTIVITY IN AN EPILEPSY MONITORING UNIT SETTING PHASE 2 | UCB SA | $23,990 | 1 |
| E41 Microburst Study | LivaNova USA, Inc. | $11,988 | 6 |
| Microburst VNS Therapy Feasibility Study in Subjects with Refractory Epilepsy | LivaNova USA, Inc. | $10,938 | 4 |
| A systematic review of the burden of disease and rescue medication treatment patterns in seizure clusters | UCB, Inc. | $6,900 | 3 |
| EXCHANGE OF CLINICAL PRACTICE AND REAL-LIFE TREATMENT WITH BRIVARACETAM (EXPERIENCE) | UCB, Inc. | $3,680 | 1 |
| A MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRIVARACETAM ADMINISTERED INTRAVENOUSLY AS TREATMENT FOR INCREASED SEIZURE ACTIVITY IN AN EPILEPSY MONITORING UNIT SETTING PHASE 2 | UCB, Inc. | $3,120 | 2 |
| Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: Results of a phase 3, open-label extension trial | UCB, Inc. | $2,300 | 1 |
| 12-month effectiveness and tolerability of brivaracetam in the real-world: interim analysis of the international, non-interventional EXPERIENCE study | UCB, Inc. | $420.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 54 | 78 | $31,044 | $7,838 |
| 2022 | 1 | 18 | 29 | $7,134 | $2,069 |
| 2021 | 3 | 121 | 186 | $89,236 | $23,802 |
| 2020 | 3 | 77 | 131 | $56,296 | $14,677 |
Total Patients
270
Total Services
424
Medicare Billing
$48,386
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2023 | 14 | 24 | $14,376 | $3,651 | 25.4% |
| 95718 | Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | Facility | 2023 | 22 | 24 | $9,288 | $2,264 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 18 | 30 | $7,380 | $1,923 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 18 | 29 | $7,134 | $2,069 | 29.0% |
| 95720 | Continuous measurement of brain wave activity with video (veeg), 12-26 hours, with health care professional analysis, interpretation and report | Facility | 2021 | 54 | 104 | $62,296 | $16,771 | 26.9% |
| 95718 | Continuous measurement of brain wave activity with video (veeg), 2-12 hours, with health care professional analysis, interpretation and report | Facility | 2021 | 45 | 48 | $18,576 | $4,970 | 26.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 22 | 34 | $8,364 | $2,061 | 24.6% |
| 95720 | Continuous measurement of brain wave activity with video (veeg), 12-26 hours, with health care professional analysis, interpretation and report | Facility | 2020 | 31 | 59 | $35,341 | $9,703 | 27.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 24 | 49 | $12,054 | $2,616 | 21.7% |
| 95718 | Continuous measurement of brain wave activity with video (veeg), 2-12 hours, with health care professional analysis, interpretation and report | Facility | 2020 | 22 | 23 | $8,901 | $2,359 | 26.5% |
About Jerzy Szaflarski
Jerzy Szaflarski is a Neurology healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275569014.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jerzy Szaflarski has received a total of $253,912 in payments from pharmaceutical and medical device companies, with $1,563 received in 2024. These payments were reported across 139 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($153,546).
As a Medicare-enrolled provider, Szaflarski has provided services to 270 Medicare beneficiaries, totaling 424 services with total Medicare billing of $48,386. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Birmingham, AL
- Active Since 06/23/2006
- Last Updated 06/29/2023
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1275569014
Products in Payments
- Briviact (Drug) $81,523
- VNS Therapy (Device) $56,613
- ONFI (Drug) $5,829
- XCOPRI (Drug) $5,491
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) $5,186
- Epidiolex (Drug) $5,166
- VNS - Sentiva (Device) $2,188
- Nayzilam (Drug) $1,280
- ACTIVA (Device) $1,082
- Cenobamate (Drug) $334.18
- RNS Neurostimulator Kit (Device) $323.56
- EPIDIOLEX (Drug) $99.65
- Vimpat (Drug) $99.16
- VNS Therapy SenTiva Model 1000 Generator (Device) $22.14
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Birmingham
Dr. Diane Counce, Md, MD
Neurology — Payments: $1.1M
Neurology $1.1M
Victor Sung
Neurology — Payments: $167,572
Neurology $167,572
Benjamin Jones, M.d, M.D
Neurology — Payments: $148,235
Neurology $148,235
Raymond Faught, Md, MD
Neurology — Payments: $122,322
Neurology $122,322
Shin Oh, Md, MD
Neurology — Payments: $99,777
Neurology $99,777
David Standaert
Neurology — Payments: $84,740
Neurology $84,740